ClinicalTrialsFinder
RecruitingPhase 4NCT03976245

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Enrollment

144 participants

Start Date

Mar 1, 2020

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
  • active RA with 5 or more swollen joints
  • seropositive
  • presence of erosions
  • failure of methotrexate and hydroxychloroquine and sulfasalazine
  • failure of Leflunomide
  • \> or equal to 18 years
  • able to provide consent
  • able to attend usual follow up visits

Exclusion Criteria9

  • no contraindication to etanercept or tofacitinib
  • active serious infection
  • active Tuberculosis
  • multiple sclerosis
  • current cancer
  • lymphoma ever
  • previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)
  • less than 18 years of age
  • unable to provide consent

Interventions

DRUGEtanercept

injection

DRUGtofacitinib

tablet

Locations(1)

Rheumatology Clinic, St. Joseph's Health Care

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03976245

Related Trials

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

NCT068415621 location

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

NCT0381634552 locations

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

NCT0710093829 locations

Biobank for Inflammatory Chronic Diseases and Osteoporosis

NCT050392161 location

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT0691680633 locations